Please provide your email address to receive an email when new articles are posted on . Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria. Combining a sodium-glucose cotransporter-2 (SGLT2) inhibitor and mineralocorticoid receptor antagonist (MRA) ...

BARCELONA -- Starting patients on empagliflozin (Jardiance) in the acute phase of a large myocardial infarction (MI) resulted in improvements in surrogate markers of heart failure (HF) and heart ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

SGLT2 inhibitors curb the action of a protein known as sodium-glucose cotransporter 2, which helps the kidneys reabsorb glucose from the blood. EMPACT-MI is the first analysis to determine if it is ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...

In the final 12 months of a 7-year study period (January 2015 to April 2022), endocrinologists accounted for 11-fold more SGLT2 inhibitor prescriptions than nephrologists, investigators report.